Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNAi
Biotech
Alnylam abandons clinical-stage Type 2 diabetes asset
Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity.
Gabrielle Masson
Oct 31, 2024 10:27am
Roche, Alnylam celebrate second ph. 2 win for blood pressure med
Mar 5, 2024 9:05am
Novo Nordisk turns RNA attention to cardio disease in new pact
Jul 17, 2023 7:45am
GSK stands by dumping cell therapies as oligo strategy heats up
Feb 17, 2023 6:30am
Northwestern U's novel RNA drug shows promise in brain cancer
Mar 10, 2021 2:00pm
Ribometrix raises $30M to drug upstream RNA with small molecules
Nov 13, 2018 7:39am
